Patients See Fewer New Docs Ranked in Bottom Tiers

Share this content:
Patients See Fewer New Docs Ranked in Bottom Tiers
Patients See Fewer New Docs Ranked in Bottom Tiers

(HealthDay News) — Patients are less likely to select a new physician ranked in the bottom of a tiered network, but often don't switch if their current physician is ranked at the bottom, according to research published online March 11 in Health Services Research.

Anna D. Sinaiko, PhD, and Meredith B. Rosenthal, PhD, both from Harvard University in Boston, estimated the impact of tier rankings on physician market share among both a plan of new patients and on the percent of a physician's patients who switch to other physicians.

RELATED: Practice Management Resource Center

The researchers found that physicians in the bottom tier (least-preferred), particularly certain specialists, had a lower market share of new patient visits than physicians with higher tier rankings.

Patients were more likely to switch health plans if their physician was in the bottom tier, but patients did not switch away from physicians whom they'd previously seen based on tier ranking.

"The effect of tiering appears to be among patients who choose new physicians and at the lower end of the distribution of tiered physicians, rather than moving patients to the 'best' performers," the researchers wrote.


  1. Sinaiko AD, Rosenthal MB. The Impact of Tiered Physician Networks on Patient Choices. BMC Health Serv Res. 2014; doi:10.1111/1475-6773.12165.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs